Truist Financial analyst Les Sulewski maintained a Buy rating on Cormedix (CRMD – Research Report) today. The company’s shares closed last ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback